Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FGFR1-4 high mRNA expression (mRNAh) as predictive biomarker for FGFR inhibitors in breast cancer (BC)

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Cinta Hierro Carbo

Citation

Annals of Oncology (2020) 31 (suppl_1): S13-S15. 10.1016/annonc/annonc83

Authors

C. Hierro Carbo1, M. Sánchez-Guixé2, J. Jiménez3, E. Garralda1, C. Saura1, P. Nuciforo3, A. Vivancos4, J. Tabernero1, J. Rodon5, V. Serra2

Author affiliations

  • 1 Medical Oncology Department, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2 Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 3 Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 4 Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 5 Department Of Investigational Therapeutics, Institute for Personalized Cancer Therapy, MDACC, Houston/US
More

Resources

The development of FGFR inhibitors, Multi-Tyrosine Kinase Inhibitors (MTKI) and specific FGFR1-4 inhibitors (FGFRinh) has been focused in FGFR-amplified (FGFRamp) BC patients (pt). However, previous results suggested that clinical benefit with FGFRinh was limited to tumours with high FGFR copy number alterations (CNA), resulting in high FGFR expression. Here, we aimed to study whether FGFR1-4 mRNAh is a predictive biomarker for both MTKI and/or FGFRinh.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings